Internal Medicine · 2017 · 15 citations · 10 references
Veterinary MedicineInfectious DiseasesPharmacotherapyBacteriologyMedical MicrobiologySepsisAntibacterial TherapyAntimicrobial TherapyBacteremia ManagementBacterial InfectionsBloodstream InfectionsMedical BacteriologyBacterial Infection TreatmentComplement In Infectious DiseaseEculizumab TherapyGram-negative Bacterial InfectionsGranulocyte Colony-stimulating Factor AdministrationIntravascular HemolysisParoxysmal Nocturnal Hemoglobinuria TherapyPseudomonas Aeruginosa Infection Treatment
Eculizumab is the complement inhibitor administered to ameliorate intravascular hemolysis in paroxysmal nocturnal hemoglobinuria. Whether or not the inhibitory mechanism may also increase the susceptibility to non-Neisserial infection is unclear. A 73-year old woman presented with bacteremia, cholecystitis and liver abscess with Pseudomonas aeruginosa. Although she had been neutropenic for 21 years, she had no history of severe infection before eculizumab had been administered. The infection with P. aeruginosa was successfully controlled with antibiotics, granulocyte colony-stimulating factor and cholecystectomy. The present case might be representative of less common bacterial infections than Neisseria spp. among patients treated with eculizumab.
10
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen, Neal S. Young, Jörg Schubert et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text
Medicine, Hematology, Pharmacology +17
How I treat paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky · Blood · 2009 · 267 citations · Full text